The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and Appointment of Senior Management Personne
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals announced leadership changes at its Board meeting on May 29, 2026. Mr. Harish Kuber retired early from the position of Company Secretary & Compliance Officer (KMP) after more than 9.5 years of service, effective from close of business on May 29, 2026. In his resignation letter, he expressed willingness to continue for a few months for smooth transition. The company appointed Ms. Rashmi Khandelwal as the new Company Secretary & Compliance Officer effective May 30, 2026. She is a qualified Company Secretary and legal professional with over 17 years of experience across prominent organisations including Crompton Greaves, ACC Limited and Yes Bank. Additionally, Mr. Samir Kazi, Executive Vice President & Head Legal, Compliance & IP, was designated as Senior Management Personnel.
This is a routine governance transition as the Company Secretary role is a mandatory KMP position under SEBI regulations. The smooth same-day replacement with an experienced professional minimises operational disruption. The resignation of a long-serving KMP may attract some investor attention but is unlikely to materially impact the stock.